Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes:a 12-year follow-up study by Peeters, S A et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Plasma matrix metalloproteinases are associated with incident cardiovascular disease
and all-cause mortality in patients with type 1 diabetes
Peeters, S A; Engelen, L; Buijs, J; Jorsal, A; Parving, H-H; Tarnow, L; Rossing, P; Schalkwijk,
C G; Stehouwer, C D A
Published in:
Cardiovascular Diabetology
DOI:
10.1186/s12933-017-0539-1
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Peeters, S. A., Engelen, L., Buijs, J., Jorsal, A., Parving, H-H., Tarnow, L., ... Stehouwer, C. D. A. (2017).
Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in
patients with type 1 diabetes: a 12-year follow-up study. Cardiovascular Diabetology, 16(1), [55].
https://doi.org/10.1186/s12933-017-0539-1
Download date: 03. Feb. 2020
Peeters et al. Cardiovasc Diabetol  (2017) 16:55 
DOI 10.1186/s12933-017-0539-1
ORIGINAL INVESTIGATION
Plasma matrix metalloproteinases are 
associated with incident cardiovascular disease 
and all-cause mortality in patients with type 1 
diabetes: a 12-year follow-up study
S. A. Peeters1,2, L. Engelen1,3, J. Buijs2, A. Jorsal4,5, H.‑H. Parving6,7,8, L. Tarnow5,7,9, P. Rossing5,7,8, C. G. Schalkwijk1,3 
and C. D. A. Stehouwer1,3*
Abstract 
Background: Altered regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue 
inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in type 1 diabetes. We investigated 
associations between plasma MMP‑1, ‑2, ‑3, ‑9, ‑10 and TIMP‑1, and cardiovascular events and all‑cause mortality in 
type 1 diabetic patients.
Methods: We prospectively followed 337 type 1 diabetic patients [mean age 41.4 years (9.6), 39% female], 170 with 
and 167 without diabetic nephropathy, with median follow‑up of 12.3 years. Survival analyses were applied to investi‑
gate differences in plasma MMP‑1, ‑2, ‑3, ‑9, ‑10, and TIMP‑1‑levels in patients with and without a cardiovascular event 
and in those who died vs survivors. All analyses were adjusted for age, sex, duration of diabetes, HbA1c, nephropathy 
and for other conventional cardiovascular risk factors.
Results: After adjustment for potential confounders, higher MMP‑2 plasma levels were significantly associated with 
higher incidence of cardiovascular events [HR 1.49 (95% CI 1.11; 1.99)], and higher plasma levels of MMP‑1 [1.38 (1.07; 
1.78)], MMP‑2 [1.60 (1.19; 2.15)] and MMP‑3 [1.39 (1.05; 1.85)] were associated with all‑cause mortality. All associations 
were independent of low‑grade inflammation and endothelial dysfunction as estimated by plasma markers. Associa‑
tions between MMP‑2 and cardiovascular events and between MMP‑3 and mortality were attenuated after further 
adjustment for eGFR and changes in eGFR.
Conclusions: Higher levels of MMP‑2 are associated with CVD and higher MMP‑1, ‑2 and ‑3 with all‑cause mortality. 
In addition, associations between MMP‑2 and CVD, and MMP‑3 and mortality were attenuated after adjustment for 
eGFR while both MMPs were associated with eGFR decline, indicating a possible mediating role of eGFR.
Keywords: Type 1 diabetes, Cardiovascular disease, All‑cause mortality, Matrix metalloproteinase, Tissue inhibitor of 
metalloproteinase, Estimated glomerular filtration rate
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The pathophysiological mechanisms leading to cardio-
vascular disease (CVD) in type 1 diabetes [1] have only 
been partly elucidated. Recent data suggest that altered 
regulation of extracellular matrix (ECM) remodeling by 
matrix metalloproteinases (MMPs) could play a role [2]. 
MMPs are proteases, which degrade ECM components 
in normal and pathological conditions. Increased plasma 
MMP-2, for example, has been associated with macro-
vascular disease by increasing vascular remodeling as 
well as thrombus formation [3, 4]. MMP production may 
be enhanced by hyperglycemia, pro-inflammatory media-
tors, reactive oxygen species and aldosterone [3]; MMP 
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activity is dependent on the number of MMPs and their 
inhibitors, such as tissue inhibitor of metalloproteinase 
(TIMP) and α2-macroglobulin [5]. In turn, increased 
activity of MMP-2 and MMP-9 is associated with low-
grade inflammation (LGI) [6] and endothelial dysfunc-
tion (ED) [7], and increased MMP-9 levels have been 
associated with renal dysfunction [8]. Therefore, LGI, ED 
and renal dysfunction constitute potential pathophysi-
ological mechanisms through which MMPs could lead to 
CVD.
Interestingly, higher plasma levels of MMP-2 and -10 
have been observed in patients with type 1 diabetes com-
pared to non-diabetic controls [9, 10]. In cross-sectional 
studies, individuals with type 1 diabetes and retinopathy 
or nephropathy showed significantly higher circulating 
levels of MMP-9 and -10 compared to individuals with-
out these complications [10, 11]. These data support the 
concept that MMPs may play an important role in the 
development of CVD. In addition, several prospective 
studies in (mainly) non-diabetic individuals have shown 
independent associations between plasma MMP-2 [12], 
MMP-9 [13] and TIMP-1 [14] and CVD, as well as asso-
ciations between MMP-1 [15], MMP-2 [12, 16, 17] and -3 
[18, 19] and all-cause mortality. However, to our knowl-
edge, no prospective studies have been reported on the 
associations between plasma MMPs or TIMP levels and 
CVD or all-cause mortality in type 1 diabetes.
In view of these considerations, we investigated associa-
tions, in type 1 diabetes, between plasma MMP-1, -2, -3, 
-9 and -10, and TIMP-1 and incident non-fatal and fatal 
cardiovascular events, as well as all-cause mortality, in a 
prospective study with more than 12 years of follow-up. 
In addition, we investigated the extent to which LGI, ED 
and renal dysfunction contributed to these associations.
Methods
Study population and design
In 1993, 199 type 1 diabetic patients with diabetic 
nephropathy and older than 18 years were enrolled in a 
prospective observational study at the outpatient clinic at 
Steno Diabetes Center. Diabetic nephropathy was defined 
as persistent macroalbuminuric [urinary albumin excre-
tion (UAE) >300  mg/24  h] in at least two out of three 
previous consecutive 24-h urine collections, presence of 
retinopathy, and absence of other kidney or urinary tract 
disease. In addition, 192 normoalbuminuric diabetic 
patients (UAE <30  mg/24  h), matched for age, sex, and 
duration of diabetes, were enrolled for comparison [20].
Patients with prior CVD (n = 24), who were lost to fol-
low-up (n = 17), with end-stage renal disease at baseline 
(n  =  7) and those with missing data on MMPs/TIMP-1 
(n = 6) were excluded from the present analysis resulting 
in a total study population of 337 individuals. Patient selec-
tion and inclusion criteria have been described in detail 
elsewhere [21]. The study was approved by the local ethics 
committee, in accordance with the Helsinki Declaration, 
and all patients gave their written informed consent.
Baseline investigations
Commercially available ELISA kits were used to meas-
ure levels of MMP-1, MMP-2, MMP-3, MMP-9, MMP-
10 and TIMP-1 in EDTA plasma samples [Human MMP 
3-Plex Kit (for MMP-1, -3 and -9), Human MMP-2-Plex 
Kit (for MMP-2 and -10) and Human TIMP-1 Kit, MSD, 
Rockville, USA], according to the manufacturer’s pro-
tocol. The MMPs were detected in both pro- and active 
form. TIMP-1 was detected in the active form. The intra- 
and inter-assay coefficients of variation were 6.6 and 
9.7% for MMP-1, 3.7 and 7.1% for MMP-2, 7.2 and 14.1% 
for MMP-3, 4.6 and 13.7% for MMP-9, 2.9 and 7.6% for 
MMP-10, and 5.1 and 7.4% for TIMP-1, respectively.
Other baseline measurements
Measurements of other biomarkers and risk factors have 
been described in detail elsewhere [20]. All clinical inves-
tigations were performed in the morning after an over-
night fast. In 88% of the normoalbuminuric and 24% of 
macroalbuminuric patients antihypertensive medication 
was never prescribed. Patients using antihypertensive 
medication were asked to stop their antihypertensive and 
diuretic treatment eight days before the examination, but 
15% of the 337 patients (27% in the nephropathy group) 
considered in our analyses did not comply with this 
recommendation.
Arterial blood pressure was measured twice, with an 
appropriate cuff size, following at least a 10-min rest in 
supine position. Mean arterial pressure (MAP) was cal-
culated as [systolic blood pressure  +  (2*diastolic blood 
pressure)]/3. Body mass index (BMI) was defined as 
weight (kg) divided by height (m) squared. An ELISA was 
used to measure UAE from 24-h urine collections. Serum 
creatinine was determined by a kinetic Jaffé method 
and we estimated the glomerular filtration rate (eGFR) 
using the chronic kidney disease epidemiology Collabo-
ration (CKD-EPI) equation [22], after creatinine was 
IDMS standardized [23]. Patients were divided into three 
groups according to their smoking status: never, former 
or current smokers.
An in-house ELISA was used to determine high-sen-
sitivity C-reactive protein (CRP) [24] and commercially 
available ELISA kits were used to measure plasma levels 
of secreted phospholipase A2 (sPLA2), interleukin-6 (IL-
6), soluble vascular cell adhesion molecule-1 (sVCAM-1) 
and soluble intercellular adhesion molecule-1 (sICAM-1).
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Follow‑up and study end‑points
All patients were followed up to the last visit at Steno Dia-
betes Center, until September 1st 2006, death (n = 83) or 
emigration (n = 3). All patients were traced through the 
national register during autumn 2006. When a patient 
died before 1 September 2006, the date of death was 
recorded and the primary cause of death was obtained 
from the death certificate, which was reviewed by two 
independent observers. Additionally, information from 
necropsy reports was included, when available. All deaths 
were classified as cardiovascular unless an unequivocal 
non-cardiovascular cause was established. At the end of 
follow up, non-fatal events were retrieved from patients’ 
records at Steno Diabetes Center or other hospital 
records. The primary endpoint of this study was fatal or 
non-fatal CVD (i.e. myocardial infarction, percutaneous 
coronary intervention, coronary bypass grafting, amputa-
tion due to ischemia, vascular surgery for peripheral ath-
erosclerotic disease and stroke). Ischemic heart disease 
was examined through a WHO questionnaire combined 
with an ECG [20]. In several patients, who were alive at 
follow-up and had more than one cardiovascular event 
during follow-up, the first event was used in the analyses. 
All-cause mortality was the secondary end-point.
Statistical analyses
All analyses were performed with SPSS version 20 for 
Windows (SPSS, Chicago, IL, USA). Triglycerides, UAE, 
CRP, IL-6, sPLA2, MMP-1, MMP-2, MMP-3, MMP-9, 
MMP-10 and TIMP-1 showed a skewed distribution 
and were  log℮ transformed prior to further analyses. 
Student’s t or Chi square tests were performed for com-
parisons of baseline characteristics between groups, 
when appropriate. Cox proportional hazards regression 
models were applied to investigate associations between 
lnMMP-1, lnMMP-2, lnMMP-3, lnMMP-9, lnMMP-10 
and lnTIMP-1 and study endpoints with adjustment for 
sex, age, duration of diabetes, HbA1c and nephropathy-
no nephropathy status (model 1). Further adjustments 
were performed for BMI, MAP, total cholesterol, smok-
ing status, antihypertensive treatment and whether or 
not patients withheld their medication prior to base-
line examinations (model 2). We used z-scores (in SD) 
of lnMMPs and lnTIMP-1 to enable direct comparisons 
between the strengths of the associations (if any) between 
the various markers and outcome measures.
An LGI score was calculated as the z-score of the aver-
age of the z-scores of lnIL-6, lnCRP, sICAM-1, and lns-
PLA2 [2, 25–27]. Similarly, an ED score was calculated as 
the z-score of the average of the z-scores of sICAM-1 and 
sVCAM-1 [2, 26, 27]. We examined the cross-sectional 
associations between lnMMP-1, lnMMP-2, lnMMP-3, 
lnMMP-9, lnMMP-10 and lnTIMP-1, and renal function 
(i.e. eGFR and ln-UAE), the LGI score and the ED score 
using linear regression analyses. Further analyses with 
adjustment of the associations between MMPs and 
TIMP-1 and study endpoints for eGFR, and ln-UAE 
(model 3), LGI (model 4) and ED (model 5) were per-
formed to evaluate the extent to which these pathophysi-
ological processes could explain the associations between 
MMPs/TIMP-1 and study outcomes. Additionally, in 
case renal function does explain part of the association 
between circulating MMPs and TIMP-1 and outcome 
measures, the possible additional influence of decrease 
in eGFR over time will also be investigated. Finally, we 
investigated whether or not any such associations dif-
fered between patients with and without nephropathy 
or between men and women by adding interaction terms 
between nephropathy or sex and MMPs or TIMP-1 to the 
models. Whenever a p value <0.1 was observed, results 
were presented for both groups separately.
Results
Additional file  1: Figure S1 depicts the flowchart con-
cerning patient selection. During a median follow-up 
of 12.3  years (interquartile range 7.7–12.5), 86 patients 
had a non-fatal (n  =  54) or fatal (n  =  49) cardiovas-
cular event. Eighty-three patients died from various 
causes: cardiovascular (n = 49), diabetes (n = 4), infec-
tion (n = 13), cancer (n = 6), suicide (n = 4) and other 
(n = 7). Patients with a cardiovascular event or who died 
during follow-up were significantly older, had a longer 
duration of diabetes, higher levels of HbA1c and a higher 
prevalence of other cardiovascular risk factors (Table 1). 
Additionally, MMP-1, MMP-2, MMP-3, MMP-9, MMP-
10 and TIMP-1 were higher in this group compared to 
patients without cardiovascular events or surviving the 
period of follow-up. Additional file 1: Table S1 shows the 
baseline characteristics according to nephropathy-no 
nephropathy status. Additional file 1: Table S2 shows the 
correlations between five MMPs and TIMP-1.
Associations of MMPs and TIMP‑1 with incident CVD
Additional file  1: Figure S2 shows the cumulative haz-
ard plots of cardiovascular events according to tertiles 
of lnMMPs and lnTIMP-1. After adjustment for age, sex, 
duration of diabetes, HbA1c and nephropathy, higher 
levels of MMPs 1, 2, 3 and 9, and TIMP-1 were signifi-
cantly associated with incidence of cardiovascular events, 
with a hazard ratio (HR) of 1.51 (95% CI 1.20; 1.91) per 1 
SD higher lnMMP-1; 1.65 (1.28; 2.13) for lnMMP-2; 1.47 
(1.13; 1.92) for lnMMP-3; 1.44 (1.17; 1.78) for lnMMP-9; 
and 1.87 (1.40; 2.49) for lnTIMP-1, respectively (Table 2, 
model 1). LnMMP-10 was not significantly associated 
with incident CVD. After further adjustment for other 
cardiovascular risk factors, antihypertensive treatment 
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Table 1 Baseline characteristics according to the incidence of a cardiovascular event or death during follow-up
Data are means (SD), medians [inter-quartile range] or percentages, as appropriate
eGFR estimated glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI); RAAS-inhibitors renin-angiotensin-aldosterone system 
inhibitors, including angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and spironolactone; MMP matrix metalloproteinase; TIMP-1 tissue 
inhibitor of metalloproteinase-1; sVCAM-1 soluble vascular cell adhesion molecule-1; sICAM-1 soluble intracellular adhesion molecule-1; CRP C-reactive protein; 
IL-6 interleukin-6; sPLA2 secreted phospholipase A2; Low-grade inflammation z-score z-score of the average of the z-scores of lnIL-6, lnCRP, sICAM-1, and lnsPLA2; 
Endothelial dysfunction z-score z-score of the average of the z-scores of sICAM-1 and sVCAM-1
CVD event No CVD event p value Patients dead at follow‑up 
n = 83
Patients alive at follow‑up 
n = 254
p value
n = 86 n = 251
Age (years) 44.5 (9.0) 40.4 (9.6) 0.001 45.3 (10.0) 40.2 (9.2) <0.001
Sex: male/female (%) 62/38 60/40 0.81 69/31 58/42 0.081
Duration of diabetes (years) 30.7 (8.7) 26.7 (7.5) <0.001 30.2 (9.9) 26.9 (7.1) 0.006
HbA1c (%) 9.5 (1.5) 8.9 (1.4) <0.001 9.6 (1.5) 8.8 (1.4) <0.001
HbA1c (mmol/mol) 80.5 (16.3) 73.4 (15.0) <0.001 81.6 (16.5) 73.1 (14.8) <0.001
Nephropathy (%) 76 42 <0.001 78 41 <0.001
Retinopathy (no/simplex/
proliferative) (%)
8/37/55 20/45/35 0.002 6/37/57 21/45/34 <0.001
BMI (kg/m2) 23.9 (3.3) 23.9 (2.8) 0.919 23.7 (3.2) 23.9 (2.8) 0.513
LDL (mmol/l) 3.64 (1.01) 3.00 (0.95) <0.001 3.60 (0.98) 3.02 (0.97) <0.001
HDL (mmol/l) 1.43 (0.41) 1.54 (0.51) 0.082 1.53 (0.48) 1.51 (0.50) 0.791
Triglycerides (mmol/l) 1.25 [0.93–1.70] 0.81[0.63–1.19] <0.001 1.29 [0.90–1.69] 0.81 [0.64–1.18] <0.001
Serum creatinine (µmol/l) 92.1 [67–135] 70 [62–81] <0.001 94.0 [68–132] 69 [62–81] <0.001
eGFR (ml/min/1.73 m2) 76.0 (31.6) 101 (21.5) <0.001 76.2 (30.9) 100.7 (22.2) <0.001
Urinary albumin excretion 
(mg/24 h)
658 [34–1983] 17 [7–532] <0.001 761 [96–2040] 17 [7–479] <0.001
Systolic blood pressure 
(mmHg)
157 (24) 136 (20) <0.001 159 (24) 136 (19) <0.001
Diastolic blood pressure 
(mmHg)
85 (13) 80 (12) 0.001 87 (14) 79 (11) <0.001
Mean arterial pressure 
(mmHg)
109 (15) 98 (13) <0.001 111 (15) 98 (13) <0.001
RAAS‑inhibitors (%) 52 21 <0.001 52 22 <0.001
Other antihypertensive 
medication (%)
64 29 <0.001 69 28 <0.001
Smoking (never/former/
current) (%)
28/19/53 38/17/45 0.234 25/17/58 39/18/43 0.05
MMP‑1 (ng/ml) 4.58 [2.78–7.17] 2.70 [1.67–4.71] <0.001 5.00 [2.74–7.03] 2.73 [1.68–4.68] <0.001
MMP‑2 (ng/ml) 229 [201–273] 185 [162–225] <0.001 231 [201–281] 185 [161–225] <0.001
MMP‑3 (ng/ml) 21.3 [13.0–28.3] 12.8 [8.6–21.3] <0.001 23.9 [16.6–29.6] 12.6 [8.5–20.2] <0.001
MMP‑9 (ng/ml) 32.5 [20.4–65.3] 21.7 [14.5–36.9] <0.001 31.2 [20.7–63.6] 21.8 [14.3–37.0] <0.001
MMP‑10 (pg/ml) 764 [618–1227] 640 [467–930] 0.002 809 [627–1235] 640 [463–916] <0.001
TIMP‑1 (ng/ml) 210 [178–265] 161 [137–204] <0.001 221 [182–277] 159 [136–204] <0.001
sVCAM‑1 (ng/ml) 1003 [842–1174] 905 [789–1105] 0.03 1038 [936–1239] 891 [789–1096] <0.001
sICAM‑1 (ng/ml) 735 [628–835] 671 [572–814] 0.076 751 [632–882] 670 [569–797] 0.003
Endothelial dysfunction 
z‑score
0.23 (0.92) −0.08 (1.02) 0.012 0.41 (0.98) −0.13 (0.97) <0.001
CRP (mg/l) 1.63 [0.64–3.24] 1.00 [0.42–2.15] 0.008 1.45 [0.60–3.30] 1.03 [0.45–2.18] 0.02
IL‑6 (pg/ml) 2.18 [1.53–3.43] 1.52 [0.99–2.34] <0.001 2.41 [1.78–3.88] 1.45 [1.00–2.22] <0.001
sPLA2 (µg/ml) 4.40 [2.80–7.00] 4.00 [2.70–6.40] 0.421 4.00 [2.80–6.50] 4.05 [2.70–6.60] 0.821
Low‑grade inflammation 
z‑score
0.32 (0.86) −0.11 (1.02) <0.001 0.3 (0.96) −0.11 (0.99) <0.001
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and continuation of antihypertensive treatment at base-
line, higher lnMMP-2 [1.49 (1.11; 1.99)] remained sig-
nificantly associated with the incidence of cardiovascular 
events (Table 2, model 2). This HR remained significant 
after further adjustment for markers of LGI and ED 
(Table 2, models 4 and 5). However, further adjustment 
for eGFR and lnUAE (Table  2, model 3) decreased the 
HR from 1.49 (1.11; 1.99) to 1.34 (0.96; 1.85). This decline 
was explained mainly by the adjustment for eGFR, which 
decreased the HR to 1.36 (0.98; 1.88), whereas adjust-
ment for lnUAE decreased the HR to 1.46 (1.08; 1.98).
Associations of MMPs and TIMP‑1 with all‑cause mortality
Additional file  1: Figure S3 shows the cumulative haz-
ard plots of all-cause mortality according to tertiles of 
lnMMPs and lnTIMP-1. After adjustment for age, sex, 
duration of diabetes, HbA1c and nephropathy, higher 
levels of MMPs 1, 2, 3, 9 and 10, and TIMP-1 were sig-
nificantly associated with all-cause mortality, with HRs 
of 1.62 (1.28; 2.06) per 1 SD higher lnMMP-1; 1.93 (1.48; 
2.51) for lnMMP-2; 1.82 (1.38; 2.41) for lnMMP-3; 1.39 
(1.14; 1.69) for lnMMP-9; 1.33 (1.06; 1.67) for lnMMP-10; 
and 2.10 (1.55; 2.85) for lnTIMP-1, respectively (Table 3, 
model 1). After adjustment for other cardiovascular 
risk factors, antihypertensive treatment and continua-
tion of antihypertensive treatment at baseline, higher 
lnMMP-1 [1.38 (1.07; 1.78)], lnMMP-2 [1.60 (1.19; 2.15)] 
and lnMMP-3 [1.39 (1.05; 1.85)] remained significantly 
associated with all-cause mortality (Table  3, model 2). 
These associations were independent of eGFR, UAE, LGI 
and ED (Table 3, models 3–5), except for the association 
between lnMMP-3 and all-cause mortality, where the 
HR decreased from 1.39 (1.05; 1.85) to 1.32 (0.95; 1.83) 
after adjustment for eGFR and lnUAE (Table 3, model 3). 
This decrease was explained mainly by the adjustment 
for eGFR, which decreased the HR to 1.32 (0.96; 1.84), 
whereas adjustment for lnUAE decreased the HR to 1.36 
(1.02; 1.82). The associations between MMP-1, MMP-2 
and MMP-3 and all-cause mortality did not materially 
change after mutual adjustments for each of the other 
MMPs, except for the association between MMP-3 and 
all-cause mortality, which decreased after adjustment for 
MMP-1 [to 1.29 (0.96; 1.73)] and MMP-2 [to 1.20 (0.88; 
1.62)].
Associations of MMPs and TIMP‑1 with eGFR, lnUAE, LGI 
and ED
Cross-sectionally and after full adjustment for cardio-
vascular risk factors, lnMMP-1, -2, -3, -10 and lnTIMP-1 
were significantly and inversely associated with eGFR at 
baseline (Table 4, model 2). LnMMP-2, -3, -10 and lnT-
IMP-1 were significantly and positively associated with 
lnUAE (Table  4, model 2). LGI was significantly associ-
ated with lnMMP-1, -9 and lnTIMP-1, and ED was signif-
icantly associated with lnMMP-1 and lnTIMP-1 (Table 4, 
model 2).
MMP‑2 and ‑3 and eGFR decline during follow‑up
The significant associations between lnMMP-2 and inci-
dent CVD and between lnMMP-3 and all-cause mortal-
ity were attenuated after adjustment for eGFR. To further 
investigate the role of eGFR in the association between 
plasma levels of MMPs and TIMP-1 on the one hand and 
incident CVD and all-cause mortality on the other, we 
investigated to what extent baseline MMPs and TIMP-1 
levels were associated with changes in eGFR during 
follow-up. In addition, we investigated to what extent 
changes in eGFR (in addition to baseline eGFR) explained 
the associations between plasma markers and outcome 
measures when added to model 2. Follow-up data on 
eGFR, during follow-up measurements in 2003 [20], were 
available in 317/337 patients; 20 patients were excluded 
because they underwent kidney transplantation dur-
ing follow-up and no data were available on eGFR pre-
transplantation (n =  14) or because no follow-up eGFR 
measurement was available (n  =  6). Median follow-up 
duration was 9.9  years [9.1; 10.5]. The median decrease 
in eGFR was −1.67  ml/min/1.73  m2/year (interquartile 
range −3.18 to −0.64). After adjustment for age, sex, 
duration of diabetes, HbA1c, smoking, MAP, BMI, total 
cholesterol, antihypertensive medication and eGFR at 
baseline, lnMMP-2 and -3 (per 1 SD increase) were asso-
ciated with decline in eGFR of −0.24 (95% CI −0.60; 
0.12) and of −0.55 (−0.94; −0.16) ml/min/1.73  m2/
year, respectively. Additional file  1: Figure S4 shows the 
decrease in eGFR per year according to tertiles of all 
MMPs and TIMP-1 after adjustment for the potential 
confounders used in model 2 plus baseline eGFR. The 
decline in eGFR was significantly greater in patients with 
nephropathy compared to those without (p < 0.001).
In the 317 patients with available data on eGFR dur-
ing follow-up, the HR for developing CVD per 1 SD 
higher lnMMP-2 decreased from 1.60 (1.17; 2.18) to 
1.40 (1.00; 1.96) after additional adjustment for baseline 
eGFR. Further adjustment for the decline in eGFR fur-
ther decreased the HR to 1.36 (0.96; 1.92). This indicates 
that MMP-2-associated decrease of eGFR may partly 
explain the association between plasma MMP-2 and 
incident CVD. Next, in these 317 patients, the HR for all-
cause mortality per 1 SD increase in lnMMP-3 decreased 
from 2.04 (1.45; 2.88) to 1.80 (1.22; 2.65) after additional 
adjustment for baseline eGFR. Further adjustment for the 
decrease in eGFR did not materially change the HR [1.79 
(1.22; 2.62)].
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Additional analyses
Stratified analyses showed that, after full adjustment for 
cardiovascular risk factors (model 2), one SD higher lnT-
IMP-1 was associated with an increase in all-cause mor-
tality in patients without [HR 3.65 (1.49; 8.92)], but not in 
those with nephropathy at baseline [HR 1.15 (0.75; 1.76)] 
(p for interaction was 0.009). In addition, after full adjust-
ment for cardiovascular risk factors (model 2), one SD 
higher lnMMP-2 was associated with an increased HR 
for all-cause mortality in men [HR 1.99 (1.34; 2.95)], but 
not in women [0.85 (0.49; 1.46)] (p for interaction was 
0.025).
Associations between plasma lnMMPs and lnTIMP-1 
on the one hand and eGFR, lnUAE, LGI and ED on the 
other differed significantly between patients with and 
without nephropathy (Additional file  1: Tables S3, S4). 
The associations between plasma lnMMPs and lnTIMP-1 
and eGFR and UAE were generally stronger in patients 
with diabetic nephropathy. Associations between mark-
ers of LGI and ED on the one hand and MMPs and 
TIMP-1 on the other did not differ consistently between 
patients with or without nephropathy.
Discussion
The present study in type 1 diabetic patients, with a 
median follow-up of 12.3  years, shows significant asso-
ciations between higher levels of plasma MMP-2 and 
incident CVD. In addition, higher plasma levels of MMP-
1, -2 and -3 were significantly associated with all-cause 
mortality. These associations were independent of car-
diovascular risk factors, LGI and ED (as expressed by 
z-scores), but partly dependent on eGFR and changes in 
eGFR. Despite the widespread correlations between the 
various MMPs and TIMP-1 (Additional file 1: Table S2), 
we showed specific associations as mentioned previously, 
which will be further discussed both with regards to cur-
rent literature, but also on possible pathophysiological 
mechanisms.
MMPs, TIMP‑1 and cardiovascular disease
Higher MMP-2-levels were independently associated 
with incident cardiovascular events, which is supported 
by the few studies available in mainly non-diabetic sub-
jects [12, 28, 29]. In patients with atrial fibrillation, higher 
baseline plasma MMP-2 levels were independently 
Table 4 Associations between plasma lnMMP-1, -2, -3, -9 and -10 and lnTIMP-1 and estimated glomerular filtration rate, 
urinary albumin excretion, low-grade inflammation and endothelial dysfunction
The standardized regression coefficient β represents the difference in eGFR (in ml/min/1.73 m2), lnUAE (in mg/24 h), LGI (in SD) or ED (in SD) per 1 SD increase in 
lnMMP-1, -2, -3, -9, and -10 and lnTIMP-1
MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline
Model eGFR Ln‑UAE LGI ED
β 95% CI p value β 95% CI p value β 95% CI p value β 95% CI p value
MMP‑1
 1 −4.15 −6.58; −1.73 0.001 −0.01 −0.13; 0.11 0.912 0.14 0.02; 0.25 0.017 −0.07 −0.18; 0.05 0.249
 2 −2.90 −5.22; −0.57 0.015 −0.03 −0.14; 0.08 0.588 0.11 0.00; 0.22 0.045 −0.12 −0.23; −0.01 0.031
MMP‑2
 1 −11.9 −14.27; −9.56 <0.001 0.29 0.16; 0.41 <0.001 −0.02 −0.14; 0.10 0.770 0.06 −0.06; 0.18 0.333
 2 −10.1 −12.48; −7.64 <0.001 0.19 0.07; 0.32 0.002 0.02 −0.11; 0.15 0.759 0.07 −0.06; 0.19 0.318
MMP‑3
 1 −12.6 −15.37; −9.92 <0.001 0.28 0.13; 0.42 <0.001 0.02 −0.12; 0.16 0.779 0.02 −0.12; 0.16 0.792
 2 −10.3 −13.05; −7.64 <0.001 0.16 0.02; 0.30 0.022 0.05 −0.09; 0.19 0.513 0.02 −0.12; 0.16 0.818
MMP‑9
 1 −0.72 −3.13; 1.70 0.559 0.02 −0.09; 0.14 0.708 0.28 0.18; 0.39 <0.001 0.05 −0.06; 0.16 0.347
 2 −0.14 −2.56; 2.29 0.912 0.02 −0.10; 0.13 0.781 0.22 0.11; 0.33 <0.001 −0.03 −0.15; 0.08 0.580
MMP‑10
 1 −6.45 −8.70; −4.19 <0.001 0.08 −0.03; 0.20 0.146 0.14 0.03; 0.25 0.010 0.13 0.03; 0.24 0.015
 2 −6.18 −8.32; −4.03 <0.001 0.11 0.00; 0.21 0.045 0.09 −0.02; 0.19 0.104 0.09 −0.02; 0.19 0.110
TIMP‑1
 1 −10.2 −12.65; −7.82 <0.001 0.26 0.14; 0.39 <0.001 0.30 0.19; 0.42 <0.001 0.23 0.11; 0.35 <0.001
 2 −8.13 −10.58; −5.68 <0.001 0.17 0.05; 0.29 0.005 0.33 0.21; 0.45 <0.001 0.22 0.10; 0.34 <0.001
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associated with cardiovascular events or death during a 
mean follow-up of 28 months [12]. In a Mexican popu-
lation, a significant association between the specific 
MMP-2-1575 A/G polymorphism and occurrence of 
myocardial infarction has been established [28]. Addi-
tionally, in patients with ST-elevation myocardial infarc-
tion undergoing percutaneous coronary intervention, 
higher plasma MMP-2-levels at baseline were associated 
with increased myocardial infarct size and decreased left 
ventricular function after four months of follow-up [29].
Various mechanisms may contribute to MMP-2-me-
diated macrovascular disease. We hypothesize that the 
occurrence of macrovascular disease can be enhanced 
by increased extracellular MMP-2 activity leading to 
plaque rupture, thrombus formation and vasoconstric-
tion caused by MMP-2-mediated cleavage of vasoactive 
peptides. This hypothesis is supported by current lit-
erature [4, 30]. Additionally, altered MMP-2 activity may 
trigger cardiovascular pathology by vascular remodeling, 
i.e. increased migration of smooth muscle vascular cells 
to the intima, increased fibrosis and decrease of elastin 
content [3, 31]. Furthermore, MMP-2 leads to sustained 
thrombus formation by increased platelet activation, 
adhesion and aggregation [4].
In our study plasma MMP-1, -3, -9, -10 and TIMP-1-lev-
els were not associated with incident CVD, which is in line 
with several prospective studies in the general population 
[32–34] and in patients with rheumatoid arthritis [35]. In 
contrast, one study in 1127 patients with stable and unsta-
ble angina showed significant associations between higher 
MMP-9 levels and cardiovascular mortality with a HR of 
2.41 (1.26; 4.60) in the upper quartile [13]. The discrepan-
cies with our study can possibly be explained by the dif-
ferences in study population and by the fact that we used 
a combined endpoint for fatal and non-fatal CVD. For the 
combined endpoint of cardiovascular death and nonfatal 
myocardial infarction in the study by Blankenberg et  al. 
[13], the unadjusted HR was 1.30 (1.11; 1.52, p  <  0.002) 
with increasing MMP-9 quartiles, but it is not clear 
whether or not this remained significant after adjustment 
for potential confounders. In our study we did not show 
an association between TIMP-1-levels and occurrence of 
CVD. This is in contrast to a recent study which showed 
a significant association between plasma TIMP-1-levels 
and recurrent cardiovascular events in patients suffering 
from previous myocardial infarction or unstable angina 
3–36  months before enrollment [14]. This discrepancy 
might be explained by the difference in study populations, 
as in our study patients with prior CVD were excluded. In 
addition, in our study more adjustments for potential con-
founders were made compared with the latter two studies.
MMPs, TIMP‑1 and all‑cause mortality
Baseline MMP-1, -2 and -3-levels were significantly asso-
ciated with all-cause mortality during follow-up. Strati-
fication according to sex showed that the association 
between MMP-2 and all-cause mortality was restricted 
to men. However, the present study can neither explain 
this sex interaction nor can it exclude the possibil-
ity of a chance finding. Thus far, no prospective studies 
have been published regarding the association between 
plasma MMPs and all-cause mortality in type 1 diabetic 
patients. In different study populations higher circulating 
levels of MMP-1 [15], MMP-2 [12, 16, 17] and MMP-3 
[18, 19] were strongly associated with all-cause mortality 
in patients with colorectal cancer [15], myocardial infarc-
tion [16, 18] or heart failure [17, 19]. MMP-1 is thought 
to be involved in cancer progression and invasion [15], 
whereas the mechanism by which MMP-3 contributed 
was not clarified [18, 19].
Plasma TIMP-1 levels did not show a significant asso-
ciation with all-cause mortality in the total study group 
and in patients with nephropathy at baseline. In contrast, 
plasma TIMP-1 was positively associated with all-cause 
mortality in patients without nephropathy at baseline. 
However, the observed interaction between TIMP-1 and 
nephropathy-status should be interpreted with caution as 
we cannot exclude the play of chance. Previous studies on 
the association between plasma TIMP-1 and mortality 
have been conflicting, both no [36] and positive associa-
tions [34, 37, 38] have been described. Positive associa-
tions between TIMP-1 and mortality were encountered 
in the general population [34], patients who underwent 
coronary angiography [37] and in patients with heart fail-
ure [38]. These diverse results do not allow us to draw a 
solid conclusion on the association between TIMP-1 and 
all-cause mortality for all study populations. However, in 
type 1 diabetes, the present study is the first to report on 
this association.
Certain genetic polymorphisms coding for MMP-1 
and MMP-3 have been associated with all-cause 
mortality [39]. The MMP-1 2G/2G polymorphism has 
been associated with increased mortality in a 3-year 
follow-up study in 99 hemodialysis patients and 133 
matched controls, HR 2.96 (1.29–6.80). In this study, 
the MMP-3 6A/6A polymorphism was non-significantly 
associated with all-cause mortality, HR 3.01 (0.88–10.3) 
and combined homozygosity of MMP-1 and MMP-3 
polymorphisms lead to a HR of 4.69 (1.72–12.8). It is 
unknown, however, how these polymorphisms influence 
MMP expression and/or activity and the underlying 
mechanism of this association thus remains to be further 
investigated.
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Potential mediation through eGFR
The association between plasma MMP-2 and CVD was 
attenuated after adjustment for baseline eGFR, which 
explained ~10% of the association. The HR decreased 
further after adjustment for decline in eGFR during fol-
low-up. This may indicate that eGFR and decline in eGFR 
play a mediating role in the association between MMP-2 
and CVD. In support, MMP-2 has been shown to induce 
complex alterations characterizing renal tubular epithe-
lial-mesenchymal transformation leading to increased 
renal fibrosis [40], which could lead to decreased renal 
function. Higher plasma MMP-2 levels may also be the 
result of decreased renal function. However, MMP-2 lev-
els are only minimally dependent on renal clearance due 
to the molecular weight of MMP-2, which is higher than 
that of albumin.
The association between MMP-3 and all-cause mor-
tality was also attenuated by eGFR and this explained 
~5% of the association. Although MMP-3 was signifi-
cantly associated with eGFR decline during follow-up, 
the association between MMP-3 and mortality did not 
materially change after adjustment for eGFR decline. 
This makes a mediating role for eGFR in the association 
between MMP-3 and all-cause mortality less likely. Taken 
together, these results show that increased plasma levels 
of MMP-2 and -3, possible due to, but to a greater extent 
independent of, decreased eGFR are positively associated 
with CVD and all-cause mortality, respectively.
Limitations
There are several limitations to our study. Firstly, 
plasma levels of MMP-1, -2, -3, -9, -10 and of TIMP-1 
were only determined at baseline. Changes in plasma 
levels over time, revealing more details about outcome 
measures, are not known. Secondly, we do not know to 
what extent plasma levels reflect the local pathological 
situation at tissue level. Thirdly, we only determined 
five different MMPs and one of the four known TIMPs, 
considered to be the most important MMPs and TIMP 
to contribute to our outcome measures, but we can-
not exclude that other MMPs and TIMPs are involved. 
Fourthly, the non-significant associations between the 
MMPs/TIMP-1 and outcome measures could be due to 
lack of statistical power, because of the relatively small 
number of events. Patients who died during follow-up 
were classified as cardiovascular unless another cause 
was established and this could have biased our results 
towards the null, resulting in underestimation of asso-
ciations. Finally, the associations between MMPs and 
TIMP-1 with eGFR changes over time might be weak-
ened by excluding those with renal transplantation 
during follow-up. Besides these limitations, the cur-
rent study, with extensive adjustments for potential 
confounders and mediators, provides additional and 
consistent information on ECM remodeling by MMPs 
and TIMP-1 preceding incident CVD and all-cause 
mortality in a large cohort of patients with type 1 dia-
betes. These results are generalizable to normo- and 
macroalbuminuric type 1 diabetic patients. Although 
microalbuminuric patients were not included in the 
current study, we have no reason to expect different 
associations in this group.
Conclusions
In patients with type 1 diabetes followed for a median 
of 12 years, higher plasma MMP-2 levels are associated 
with incident CVD and higher plasma MMP-1, MMP-
2, MMP-3 are associated with all-cause mortality. These 
associations are independent of cardiovascular risk fac-
tors, low-grade inflammation and endothelial dysfunc-
tion. However, baseline eGFR and decline in eGFR during 
follow-up attenuated the association between MMP-2 
and CVD as well as the association between MMP-3 
and all-cause mortality; eGFR may thus, in part, mediate 
these associations.
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